Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

5.720
-0.260-4.35%
Volume:86.64M
Turnover:495.08M
Market Cap:107.31B
PE:29.90
High:5.870
Open:5.870
Low:5.620
Close:5.980
52wk High:9.120
52wk Low:3.137
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:1.75
T/O Rate:0.46%
Dividend:0.09
Dividend Rate:1.65%
EPS(LYR):0.191
ROE:15.40%
ROA:5.07%
PB:2.83
PE(LYR):29.90
PS:3.09

Loading ...

Earning Preview: SINO BIOPHARM revenue is expected to increase by 6%, and institutional views are bullish

Earnings Agent
·
Mar 19

SINO BIOPHARM Achieves MSCI ESG Rating Upgrade to AA Level

Stock News
·
Yesterday

Sino Biopharmaceutical upgraded to AA in MSCI ESG Ratings

Reuters
·
Yesterday

Sino Biopharmaceutical Stock Slips 4.3% in Hong Kong

Dow Jones
·
Yesterday

Sino Biopharmaceutical Stock Slides 3.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 19

Sino Biopharmaceutical Gets China Nod for Osteoarthritis Drug Trial

MT Newswires Live
·
Mar 17

China Biopharma's Novel Drug TRD221 Receives NMPA Clearance for Clinical Trials

Stock News
·
Mar 17

BRIEF-Sino Biopharmaceutical Says TRD221 Receives NMPA Clinical Trial Approval For Osteoarthritis Treatment

Reuters
·
Mar 17

Sino Biopharmaceutical - Trd221 Receives Nmpa Clinical Trial Approval for Osteoarthritis Treatment

THOMSON REUTERS
·
Mar 17

Sino Biopharm (01177) Sets 26 Mar 2026 Board Meeting to Approve FY 2025 Results and Mull Final Dividend

Bulletin Express
·
Mar 16

Sino Biopharmaceutical Stock Advances 2.4% in Hong Kong

Dow Jones
·
Mar 16

Sino Biopharmaceutical wins NMPA CDE consent to submit TQB3454 bile duct cancer marketing application

Reuters
·
Mar 16

Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Mar 13

Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival

MT Newswires Live
·
Mar 12

BRIEF-Sino Biopharmaceutical Reports Positive Results On Phase III Clinical Study Of TQB3454 IDH1 Inhibitor

Reuters
·
Mar 12

SINO BIOPHARM (01177) achieves first-in-China Phase III success for IDH1 inhibitor TQB3454; NMPA filing imminent

Bulletin Express
·
Mar 12

Thailand's Wealthiest Family Prepares Another IPO

Deep News
·
Mar 12

Sino Biopharmaceutical - Positive Results on Phase Iii Clinical Study of Tqb3454 Idh1 Inhibitor for Biliary Tract Cancer

THOMSON REUTERS
·
Mar 12

BRIEF-Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA

Reuters
·
Mar 11

Clinical Trial for SINO BIOPHARM's (01177) TQB3205 Pan-KRAS Inhibitor Receives NMPA Approval

Stock News
·
Mar 11